Akèy › Limfòm folikilè › Massachusetts › Boston
Etid klinik pou Limfòm folikilè nan Boston, MA
17 etid pou Limfòm folikilè ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Ap rekriteFaz 3
- Tufts Medical Center, Boston
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
Ap rekriteFaz 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Ap rekriteFaz 3
- Research Site, Boston
- Research Site, Boston
NEO100 and High-Grade Meningioma
Ap rekriteFaz 2
- Tufts Medical Center, Boston
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Ap rekriteFaz 3
- Beth Israel Deaconess Medical Center, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Ap rekriteFaz 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Ap rekriteFaz 3
- Local Institution - 0145, Boston
- Local Institution - 0244, Boston
- Local Institution - 0247, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
Odronextamab in Low Tumor Volume Advanced FL
Ap rekriteFaz 2
- Beth Israel Deaconess Medical Center, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Ap rekriteFaz 2
- Beth Israel Deaconess Medical Center, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
Ap rekriteFaz 1
- Beth Israel Deaconess Medical Center, Boston
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Ap rekriteFaz 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Etid Limfòm folikilè nan lòt vil
- New York City, NY24 etid
- Milwaukee, WI19 etid
- Nashville, TN18 etid
- Houston, TX18 etid
- Baldwin Park, CA16 etid
- Seattle, WA15 etid
- Durham, NC15 etid
- Columbus, OH13 etid
- Salt Lake City, UT13 etid
- Chicago, IL12 etid
- San Antonio, TX12 etid
- Philadelphia, PA12 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.